Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors - The Lancet Oncology
Crosstalk between the MET and EGFR pathways. HGF: hepatocyte growth... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. - Abstract - Europe PMC
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
PLOS ONE: Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling - ScienceDirect
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib - Journal of Thoracic Oncology
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Crosstalk between c-Met and EGFR. a, b The tyrosine kinase receptors... | Download Scientific Diagram
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody* - Journal of Biological Chemistry
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer | PGPM
Functional crosstalk of HGF-MET signaling pathway with EGFR and VEGFR... | Download Scientific Diagram
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation - Lung Cancer
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
BioModels
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer | Clinical Cancer Research
